Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373656" target="_blank" >RIV/00216208:11130/17:10373656 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/17:10373656

Result on the web

<a href="https://doi.org/10.1182/blood-2016-07-726307" target="_blank" >https://doi.org/10.1182/blood-2016-07-726307</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/blood-2016-07-726307" target="_blank" >10.1182/blood-2016-07-726307</a>

Result language

angličtina

Original language name

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Original language description

A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of &lt;= 10(-25), comparable to real-time quantitative polymerase chain reaction (RQ-PCR)-based MRD detection via antigen-receptor rearrangements. Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their contribution in separating BCP-ALL cells from normal/regenerating BCP cells in multidimensional principal component analyses. After 5 multicenter design-test-evaluate-redesign phases with a total of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were selected, which allowed separation between normal and malignant BCP cells in 99% of studied patients. These 2 tubes were tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone marrow follow-up samples of 178 BCP-ALL patients. Comparison with RQ-PCR-based MRD data showed a clear positive relation between the percentage concordant cases and the number of cells acquired. For those samples with &gt; 4 million cells acquired, concordant results were obtained in 93% of samples. Most discordances were clarified upon high-throughput sequencing of antigen-receptor rearrangements and blind multicenter reanalysis of flow cytometric data, resulting in an unprecedented concordance of 98% (97% for samples withMRD &lt; 0.01%). In conclusion, the fully standardized EuroFlow BCP-ALLMRD strategy is applicable in &gt; 98% of patients with sensitivities at least similar toRQ-PCR (&lt;= 10(-25)), if sufficient cells (&gt; 4310 6, preferablymore) are evaluated.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood

ISSN

0006-4971

e-ISSN

—

Volume of the periodical

129

Issue of the periodical within the volume

3

Country of publishing house

US - UNITED STATES

Number of pages

11

Pages from-to

347-357

UT code for WoS article

000396529800012

EID of the result in the Scopus database

2-s2.0-85018677964